vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and GILAT SATELLITE NETWORKS LTD (GILT). Click either name above to swap in a different company.
GILAT SATELLITE NETWORKS LTD is the larger business by last-quarter revenue ($152.7M vs $83.5M, roughly 1.8× BillionToOne, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs 4.1%, a 2.7% gap on every dollar of revenue.
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Gilat Satellite Networks Ltd. is an Israeli public company. It provides satellite-based broadband communications technology, its main expertise being the development, manufacture, and marketing of ground-based satellite systems for global communication via satellites.
BLLN vs GILT — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $152.7M |
| Net Profit | $5.7M | $6.3M |
| Gross Margin | 69.9% | 35.8% |
| Operating Margin | 11.5% | 5.4% |
| Net Margin | 6.8% | 4.1% |
| Revenue YoY | 117.4% | — |
| Net Profit YoY | 138.3% | — |
| EPS (diluted) | $0.10 | $57016808.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $83.5M | — | ||
| Q2 25 | — | $152.7M | ||
| Q3 24 | $38.4M | — | ||
| Q2 24 | — | $126.6M | ||
| Q2 23 | — | $106.9M | ||
| Q2 22 | — | $98.2M |
| Q3 25 | $5.7M | — | ||
| Q2 25 | — | $6.3M | ||
| Q3 24 | $-14.9M | — | ||
| Q2 24 | — | $9.9M | ||
| Q2 23 | — | $-2.0M | ||
| Q2 22 | — | $-5.2M |
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | 35.8% | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | 39.7% | ||
| Q2 23 | — | 33.8% | ||
| Q2 22 | — | 29.6% |
| Q3 25 | 11.5% | — | ||
| Q2 25 | — | 5.4% | ||
| Q3 24 | -32.9% | — | ||
| Q2 24 | — | 9.8% | ||
| Q2 23 | — | 0.4% | ||
| Q2 22 | — | -4.0% |
| Q3 25 | 6.8% | — | ||
| Q2 25 | — | 4.1% | ||
| Q3 24 | -38.8% | — | ||
| Q2 24 | — | 7.8% | ||
| Q2 23 | — | -1.9% | ||
| Q2 22 | — | -5.3% |
| Q3 25 | $0.10 | — | ||
| Q2 25 | — | $57016808.00 | ||
| Q3 24 | $-1.47 | — | ||
| Q2 24 | — | $56622204.00 | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $64.9M |
| Total DebtLower is stronger | $55.0M | $56.5M |
| Stockholders' EquityBook value | $-239.5M | $315.8M |
| Total Assets | $327.5M | $575.9M |
| Debt / EquityLower = less leverage | — | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $195.2M | — | ||
| Q2 25 | — | $64.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $93.7M | ||
| Q2 23 | — | $87.4M | ||
| Q2 22 | — | $70.1M |
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | $56.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $2.0M | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | $-239.5M | — | ||
| Q2 25 | — | $315.8M | ||
| Q3 24 | $-242.9M | — | ||
| Q2 24 | — | $282.8M | ||
| Q2 23 | — | $255.0M | ||
| Q2 22 | — | $245.7M |
| Q3 25 | $327.5M | — | ||
| Q2 25 | — | $575.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $416.9M | ||
| Q2 23 | — | $371.6M | ||
| Q2 22 | — | $376.0M |
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.01× | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | — |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $13.8M | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $8.2M | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | $6.5M | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $1.7M | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | 7.7% | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.3% | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | 8.8% | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.2% | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.83× | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
GILT
Segment breakdown not available.
